Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel†‡
An Analysis of Gynecologic Oncology Group Trials
Version of Record online: 17 JUN 2009
Copyright © 2009 American Cancer Society
Volume 115, Issue 18, pages 4210–4217, 15 September 2009
How to Cite
Farley, J. H., Tian, C., Rose, G. S., Brown, C. L., Birrer, M. and Larry Maxwell, G. (2009), Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel. Cancer, 115: 4210–4217. doi: 10.1002/cncr.24482
The following Gynecologic Oncology Group member institutions participated in this study: University of Alabama at Birmingham; Duke University Medical Center; Abington Memorial Hospital; University of Rochester Medical Center; Walter Reed Army Medical Center; Wayne State University; University of Minnesota Medical School; Emory University Clinic; University of Mississippi Medical Center; Colorado Gynecologic Oncology Group, P.C.; University of California at Los Angeles; University of Washington; University of Pennsylvania Cancer Center; Milton S. Hershey Medical Center; Georgetown University Hospital; University of Cincinnati; University of North Carolina School of Medicine; University of Texas Southwestern Medical Center at Dallas; Indiana University School of Medicine; Wake Forest University School of Medicine; Albany Medical College; University of California Medical Center at Irvine; Tufts-New England Medical Center; Rush-Presbyterian–St. Luke's Medical Center; State University of New York Downstate Medical Center; University of Kentucky; Community Clinical Oncology Program, the Cleveland Clinic Foundation; Johns Hopkins Oncology Center; State University of New York at Stony Brook; Eastern Pennsylvania GYN/ONC Center, P.C.; Washington University School of Medicine; Cooper Hospital/University Medical Center; Columbus Cancer Council; University of Massachusetts Medical School; Fox Chase Cancer Center; Medical University of South Carolina; Women's Cancer Center, University of Oklahoma; University of Virginia Health Sciences Center; University of Chicago; Tacoma General Hospital, Thomas Jefferson University Hospital; Case Western Reserve University; Tampa Bay Cancer Consortium; North Shore University Hospital; Gynecologic Oncology Network; Oregon Health Sciences University; University of Southern California at Los Angeles; University of Miami School of Medicine; Stanford University Medical Center; Eastern Virginia Medical School; University of Arizona Health Science Center; Mayo Clinic; and Long Island Jewish Medical Center.
This article is US Government work and, as such, is in the public domain in the United States of America.
- Issue online: 4 SEP 2009
- Version of Record online: 17 JUN 2009
- Manuscript Accepted: 5 FEB 2009
- Manuscript Revised: 28 JAN 2009
- Manuscript Received: 10 DEC 2008
- 12Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001; 19: 1001-1007., , , et al.